Video Series

Payer decision-makers discuss defining value among agents for unintended pregnancy, uterine fibroids, and endometriosis.

A panel of experts discuss treatment selection among contraceptive agents and evolving treatment strategies for uterine fibroids and endometriosis.

Dr Leandro N. Slipczuk highlights the importance of cardiovascular treatment guidelines when deciding on patient care for those with ASCVD.

Three cardiovascular experts discuss the future of lipid management for patients with high-risk ASCVD.

Dr Ayman Al-Hendy discusses the diagnosis of uterine fibroids and endometriosis along with treatment goals.

Dr Steven McCarus discusses the journey of a patient with endometriosis through the health care system.

Drs Brinton and Slipczuk go into detail regarding an ideal multidisciplinary team for ASCVD treatment.

Drs Riddock and Slipczuk define “optimal care” for ASCVD from a system-level perspective with the use of quality metrics.

Payer considerations regarding unintended pregnancy is discussed by Maria Lopes, MD, MS, and Kevin Stephens Sr., MD, JD.

Ayman Al-Hendy, MD, PhD identifies risk factors for development of US and endometriosis.

Drs Steven Levine, Patricia Ares-Romero, Samuel Nordberg, Martin Rosenzweig, and Carrie Jardine share insight on the future treatment landscape for TRD.

Dr Martin Rosenzweig discusses the importance of data collection to improve patient care in TRD as well as alternative payment models.

Dr Eliot Brinton elaborates on unmet needs in lipid management and how they can be remedied.

Ian Riddock, MD, and Leandro N. Slipczuk, MD, PhD, discuss the importance of LDL-C management as part of the discharge plan for patients, as well as ensuring continuity of care from the inpatient to outpatient setting.

Kevin Stephens, Sr. MD, JD examines key drivers of healthcare utilization for women of childbearing years.

Steven McCarus, MD FACOG highlights the shift away from surgical treatment toward medical therapy in UF and endometriosis.

Drs Martin Rosenzweig and Samuel Nordberg share perspectives for integrated policymaking in behavioral health, as well as payer and provider collaboration for TRD.

Carrie Jardine leads a discussion on varying prior authorization policies for alternative therapies for TRD along with implications to patients.

Our panel concludes with their plans to incorporate RWE into MM management in the future.

Dr Baljević discusses unmet needs that are typically seen in the management of MM.

Dr Brinton highlights the importance of adjunct therapies in LDL management.

Dr Riddock explains how the ASCVD treatment landscape lends itself to initiation of therapy beyond statins in the inpatient setting.

Dr Lopes, OB-GYN and payer, discusses a focus on screening and prevention and availability of contraception among health plans in women’s health.

Ayman Al-Hendy, MD, PhD and Maria Lopes, MD, MS discuss common concerns that women seek care for during their reproductive years, including uterine fibroids, endometriosis, and unintended pregnancy.

Key opinion leaders discuss navigation through challenges with appropriate coding for TRD treatment.

Carrie Jardine and Martin Rosenzweig, MD, share considerations for benefit design in behavioral health.

Eliot Brinton, MD, provides a warning concerning “maximally-tolerated statin dosing” and provides general guidance for optimal dosing.

Ian Riddock, MD, describes the high-risk patient with ASCVD that is appropriate for early intensive lipid lowering.

Dr Richter delves into how we can better educate patients and physicians on RWE to improve decision-making.

The panel moves the discussion to non-comparative RWE and how that can play a part in their decision-making for MM therapy.